Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Dalfampridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA1 known ✓ | Q09470 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.44 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.44 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dalfampridine SCHEMBL11585366 | 0.83 | ALDH1A1 (0.56) | MEN1KMT2AMAPTALDH1A1CYP2D6 | |
| Aniline SCHEMBL3769652 | 0.79 | TSHR (0.55) | MAPTCYP2D6TSHRMAPK1SMN1; SMN2 | |
| Dalfampridine SCHEMBL22382689 | 0.79 | ALDH1A1 (0.65) | MEN1KMT2AMAPTALDH1A1CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL6276036 | 0.79 | PLOD2 (0.50) | MEN1KMT2AMAPTALDH1A1CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL3614047 | 0.79 | PLOD2 (0.50) | MEN1KMT2AMAPTALDH1A1CYP2D6 | |
| Dalfampridine SCHEMBL27592753 | 0.79 | MAPT (0.72) | MEN1KMT2AMAPTALDH1A1CYP2D6 | |
| Trifluoroacetic Acid SCHEMBL25246048 | 0.78 | PLOD2 (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2PLOD2 | |
| Isonicotinic Acid SCHEMBL28101509 | 0.78 | NAPRT (0.74) | MEN1KMT2AALDH1A1CYP2D6TSHR | |
| Trifluoroacetic Acid SCHEMBL8138931 | 0.78 | PLOD2 (0.40) | MEN1KMT2AALDH1A1TSHRPLOD2 | |
| Trifluoroacetic Acid SCHEMBL5532877 | 0.78 | PLOD2 (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2PLOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116783199-A | Pyrazolo [1,5-A ] pyrazine derivatives as BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| US-10723724-B2 | Compounds for treating degenerative diseases of central nervous system or brain tumor, and uses thereof | SUN YAT-SEN UNIVERSITY (CN) | 2020-07-28 | — | — | US | disclosed |
| CN-110372703-A | Five-ring heterocycles miazines compound and application thereof | 罗欣生物科技（上海）有限公司 | 2019-10-25 | — | — | CN | disclosed |
| US-20190202817-A1 | COMPOUNDS FOR TREATING DEGENERATIVE DISEASES OF CENTRAL NERVOUS SYSTEM OR BRAIN TUMOR, AND USES THEREOF | SUN YAT-SEN UNIVERSITY (CN) | 2019-07-04 | — | — | US | disclosed |
| CN-106279136-B | Compound and its application for treating central nervous system degenerative disease or brain tumor | 中山大学 | 2019-06-21 | — | — | CN | disclosed |
| CN-107849010-A | 3, 3-difluoropiperidine carbamate heterocycles as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-106279136-A | Treat central nervous system degenerative disease or the compound of the cerebral tumor and application thereof | 中山大学 | 2017-01-04 | — | — | CN | disclosed |
| CN-1751042-B | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LTD | 2011-02-23 | — | — | CN | disclosed |
| CN-1856304-A | Heteroaromatic ureas that modulate the function of the capsaicin-1 receptor (VR1) | MERCK SHARP & DOHME (GB) | 2006-11-01 | — | — | CN | disclosed |
| CN-1751042-A | Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LTD (GB) | 2006-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202817-A1 | COMPOUNDS FOR TREATING DEGENERATIVE DISEASES OF CENTRAL NERVOUS SYSTEM OR BRAIN TUMOR, AND USES THEREOF | SGK1, SGK3, SGK2 | KCNA1 4373/4885MEN1 1436/4885KMT2A 2978/4885 |
| US-10723724-B2 | Compounds for treating degenerative diseases of central nervous system or brain tumor, and uses thereof | SGK1, SGK3, SGK2 | KCNA1 4373/4885MEN1 1436/4885KMT2A 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.